Dr. Abhijit Saha

About

Prof. Abhijit Saha has about 16 years of work experience in the fields of teaching and research.
He served in different faculty positions for more than 16 years in the College of Pharmaceutical Sciences, Berhampur, Odisha, under Biju Patnaik University of Technology, and guided more than 30 Master's Degree (M.Pharm in Pharmaceutical chemistry and Pharmaceutical analysis) Students in their Research Projects. He has qualified GATE exam in 2006 and 2008. He has received his Ph.D degree from Biju Patnaik University of Technology, Odisha. Dr. Saha has successfully handled one UGC Research Project, New Delhi, Govt. of India, in 2013. He has published more than 15 research papers in internationally reputed journals, as well as 2 book chapters and 3 papers in the proceedings of national and international conferences. Prof. Saha is the reviewer of Current Drug Metabolism, Bentham Science. His areas of research interest are Drug Designing, Synthesis of new Anticancer compounds, Analysis, and Phytochemical extraction.

Employment

• Dr. B. C. Roy College of Pharmacy and Allied health Science PROFESSOR
  2025 - Present

Education

• Biju Patnaik University of Technology Ph. D
  ? - 2023

Projects & Funding

Projects & funding information is unavailable.

Publications (12)

• Analogue-Based Design, Synthesis, and Antimicrobial Study of Aryl and Heteroaryl Sulfonamides as Multi-Targeted Antimicrobial Compounds
  Russian Journal of Bioorganic Chemistry 2025 DOI: 10.1134/s1068162024606311
  +Save
• Analogue Based Design, Synthesis, Biological Evaluation, and Molecular Docking of Some Thalidomide Metabolites as Selective Cytotoxic and Antiangiogenic Agents against Multiple Myeloma
  Russian Journal of Bioorganic Chemistry 2022 DOI: 10.1134/s1068162022010022
  +Save
• A VALIDATED STABILITY INDICATING RP-HPLC METHOD FOR ESTIMATION OF AVAPRITINIB IN BULK AND TABLET DOSAGE FORM
  International Journal of Applied Pharmaceutics 2022 DOI: 10.22159/ijap.2022v14i2.43432
  +Save
• Pharmacophore Based Design of Probable FGFR-1 Inhibitors from the 3D Crystal Structure of Infigratinib - A Drug Used in the Treatment of Cholangiocarcinomas
  Letters in Drug Design and Discovery 2022 DOI: 10.2174/1570180818666211007113720
  +Save
• RATIONAL DESIGN, SYNTHESIS AND IN VITRO EVALUATION OF N-(4-ETHOXYPHENYLSULFONYL)-L-GLUTAMIC ACID ANALOGUES AS ANTIANGIOGENIC AND ANTICANCER AGENTS ON MULTIPLE MYELOMA
  INDIAN DRUGS 2021 DOI: 10.53879/id.57.12.12807
  +Save
• Design, synthesis and in vitro evaluation of 2-(quinoline-8-sulfonamido)pentanedioic acid analogues as antiangiogenic and antitumor agents on multiple myeloma
  Asian Journal of Chemistry 2021 DOI: 10.14233/ajchem.2021.23238
  +Save
• Design, synthesis, molecular docking and in vitro evaluation of n -(4-ethoxyphenylsulfonyl)pyrrolidine-2-carboxylic acid analogues as antiangiogenic and anticancer agents on multiple myeloma
  Asian Journal of Chemistry 2021 DOI: 10.14233/ajchem.2021.23064
  +Save
• S. MISHRA, K. SARKER, A. GHOSH, A. SAHA, S. SEN*
  In silico Enhancement of VEGFR-2 Binding Properties of 5-Amino-2-(3,4-Dimethoxyphenylsulfonamido)-5-Oxopentanoic Acid (SM-1) for Improving its Anticancer Activity 2021
  +Save
• Design, synthesis, molecular docking and in vitro evaluation of N-(4-methoxyphenylsulfonyl)pyrrolidine-2-carboxylic acid analogues as antiangiogenic and anticancer agents on multiple myeloma
  Asian Journal of Chemistry 2020 DOI: 10.14233/ajchem.2020.22957
  +Save
• Transmuting methotrexate in to a potential binder of dihydrofolate reductase
  International Journal of Pharmaceutical Sciences Review and Research 2013
  +Save